A seven-gene CpG-island methylation panel predicts breast cancer progression

Abstract

BackgroundDNA methylation regulates gene expression, through the inhibition/activation of gene transcription of methylated/unmethylated genes. Hence, DNA methylation profiling can capture pivotal features of gene expression in cancer tissues from patients at the time of diagnosis. In this work, we analyzed a breast cancer case series, to identify DNA methylation determinants of metastatic versus non-metastatic tumors.MethodsCpG-island methylation was evaluated on a 56-gene cancer-specific biomarker microarray in metastatic versus non-metastatic breast cancers in a multi-institutional case series of 123 breast cancer patients. Global statistical modeling and unsupervised hierarchical clustering were applied to identify a multi-gene binary classifier with high sensitivity and specificity. Network analysis was utilized to quantify the connectivity of the identified genes.ResultsSeven genes (BRCA1, DAPK1, MSH2, CDKN2A, PGR, PRKCDBP, RANKL) were found informative for prognosis of metastatic diffusion and were used to calculate classifier accuracy versus the entire data-set. Individual-gene performances showed sensitivities of 63–79 %, 53–84 % specificities, positive predictive values of 59–83 % and negative predictive values of 63–80 %. When modelled together, these seven genes reached a sensitivity of 93 %, 100 % specificity, a positive predictive value of 100 % and a negative predictive value of 93 %, with high statistical power. Unsupervised hierarchical clustering independently confirmed these findings, in close agreement with the accuracy measurements. Network analyses indicated tight interrelationship between the identified genes, suggesting this to be a functionally-coordinated module, linked to breast cancer progression.ConclusionsOur findings identify CpG-island methylation profiles with deep impact on clinical outcome, paving the way for use as novel prognostic assays in clinical settings.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1412-9) contains supplementary material, which is available to authorized users.

Noninvasive diagnosis of urothelial cancer in urine using DNA hypermethylation signatures—Gender matters

“…When using LASSO for parameter shrinkage, we aimed to create a more stable model by restricting the number of model coefficients and feature selections and reducing unwanted effects due to overfitting . In line with previous studies, the combination of individual CpGs appeared to improve the diagnostic reliability for UCa. However, the calculated sets were dependent on the type of control group, and only one CpG (35 CpG 7) was part of the LASSO‐derived CpG sets that could distinguish between both UCa and UCt, and UCa and PCt.…”

Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors

“…Effective molecular characterization of patients' tumors (26,32), for example, for alterations of signal transducing molecules, further extended these approaches. For example, EGFR mutations predict better response to the kinase inhibitor erlotinib, whereas mutated KRAS associates to worse prognosis and lack of response to erlotinib (47).…”

“…ERK triggering correlated with phosphorylation of MEK1 at the S298 activatory site (30) and hypophosphorylation at the T292 inhibitory site (Supplementary Table S1A), as a feedback mechanism driven by PAK1/ ERK1/ERK2 (31). Downstream targets included NFKB and TP53 (32), with AKT-mediated MDM2 phosphorylation for TP53 ubiquitination. Seven of the identified pathways were found to include members of the PTEN/PIK3CA/AKT signaling network (Supplementary Table S1D).…”

BET proteins regulate homologous recombination‐mediated DNA repair: BRCAness and implications for cancer therapy

“…Epigenetic BRCAness has been linked to poor outcome, but its role in respect to platinum‐based regimens or PARP inhibitors remains uncertain . Under these premises, pharmacologically induced BRCAness could represent a solid strategy to sensitize TNBC with no BRCA1 epigenetic inactivation or mutation to genotoxic agents.…”